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Shp2, a ubiquitously expressed protein tyrosine 
phosphatase  (PTP),  is  implicated  in  multiple 
cell signaling processes, such as the RAS–MAP 
kinase, JAK–STAT, PI3K–AKT, NF-B, and 
NFAT  pathways  (Neel  et  al.,  2003;  Tonks, 
2006; Xu and Qu, 2008). It contains two tan-
dem SH2 domains and a PTP domain. The 
SH2  domains,  in  particular,  the  N-terminal 
SH2 (N-SH2) domain, mediate the binding of 
Shp2 to other signaling proteins via phosphory-
lated tyrosine (pY) residues in a sequence- 
specific fashion (Zhao et al., 2003; Pawson, 
2004; Songyang and Cantley, 2004; Waksman 
and  Kuriyan,  2004).  This  directs  Shp2  to   
the appropriate subcellular location and helps 
determine the specificity of substrate–enzyme 
interactions. Shp2 is normally self-inhibited   
by hydrogen bonding of the backside of the   
N-SH2 domain loop to the deep pocket of the 
PTP  domain  (Eck  et  al.,  1996;  Hof  et  al., 
1998). The self-inhibition leads to occlusion of 
the phosphatase catalytic site and a distortion of 
the pY-binding site of N-SH2. Ligands with 
pY residues activate Shp-2 by binding the SH2 
domains (primarily the N-SH2 domain), thereby 
disrupting the interaction between N-SH2 and 
PTP  domains  and  exposing  the  phosphatase 
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Activating mutations in protein tyrosine phosphatase 11 (Ptpn11) have been identified in 
childhood acute leukemias, in addition to juvenile myelomonocytic leukemia (JMML), which 
is a myeloproliferative disorder (MPD). It is not clear whether activating mutations of this 
phosphatase play a causal role in the pathogenesis of acute leukemias. If so, the cell origin 
of leukemia-initiating stem cells (LSCs) remains to be determined. Ptpn11E76K mutation is 
the most common and most active Ptpn11 mutation found in JMML and acute leukemias. 
However, the pathogenic effects of this mutation have not been well characterized. We 
have created Ptpn11E76K conditional knock-in mice. Global Ptpn11E76K/+ mutation results in 
early embryonic lethality. Induced knock-in of this mutation in pan hematopoietic cells 
leads to MPD as a result of aberrant activation of hematopoietic stem cells (HSCs) and 
myeloid progenitors. These animals subsequently progress to acute leukemias. Intriguingly, 
in addition to acute myeloid leukemia (AML), T cell acute lymphoblastic leukemia/lym-
phoma (T-ALL) and B-ALL are evolved. Moreover, tissue-specific knock-in of Ptpn11E76K/+ 
mutation in lineage-committed myeloid, T lymphoid, and B lymphoid progenitors also 
results in AML, T-ALL, and B-ALL, respectively. Further analyses have revealed that Shp2 
(encoded by Ptpn11) is distributed to centrosomes and that Ptpn11E76K/+ mutation promotes 
LSC development, partly by causing centrosome amplification and genomic instability. Thus, 
Ptpn11E76K mutation has non–lineage-specific effects on malignant transformation of 
hematopoietic cells and initiates acute leukemias at various stages of hematopoiesis.
© 2011 Xu et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Keilhack et al., 2005). In addition, Ptpn11 disease mutations, 
especially leukemia mutations, enhance the binding of mu-
tant Shp2 to signaling partners (Araki et al., 2004; Fragale   
et al., 2004; Kontaridis et al., 2006; Yu et al., 2006). Never-
theless, as the biochemical basis for the positive role that Shp2 
phosphatase plays in cell signaling and other cellular processes 
is unknown, the cellular and molecular mechanisms by which 
Ptpn11 gain-of-function (GOF) mutations induce JMML are 
not well understood. Furthermore, Ptpn11 GOF mutations 
are also found in myelodysplastic syndromes (also known as 
pre–acute myeloid leukemia (AML); 10%), B cell acute lym-
phoblastic  leukemia/lymphoma  (B-ALL;  7%),  AML  (4%; 
Loh et al., 2004a; Tartaglia et al., 2004), and sporadic solid 
tumors (Bentires-Alj et al., 2004). Although previous studies 
have shown that Ptpn11 GOF mutations induce cytokine   
hypersensitivity in myeloid progenitors (Chan et al., 2005; 
Schubbert et al., 2005; Yu et al., 2006) and MPD in mice 
(Araki et al., 2004; Mohi et al., 2005; Chan et al., 2009; Xu 
et al., 2010), it is unclear whether Ptpn11 GOF mutations 
also play a causal role in acute leukemias. If so, the underlying 
mechanisms remain to be determined.
To address these important questions and to further dis-
sect the role of Shp2 in health and disease, we created a line 
of conditional knock-in mice with the most common and 
most active Ptpn11 mutation (E76K) found in JMML and 
acute leukemias (Tartaglia et al., 2003, 2006; Kratz et al., 
2005; Aoki et al., 2008). Global Ptpn11E76K/+ mutation results 
in early embryonic lethality. Induced knock-in of this muta-
tion in pan hematopoietic cells leads to MPD followed by 
malignant evolution into various acute leukemias. Further-
more, we have discovered that Ptpn11E76K/+ mutation induces 
leukemia-initiating stem cell (LSC) development not only in 
stem cells but also in lineage-committed progenitors. This 
non–lineage/stage-specific  effect  of  Ptpn11E76K/+  mutation 
on hematopoietic cell transformation appears to be partially 
associated with the disturbance of a previously unrecognized 
function of Shp2 in centrosomes and maintenance of chro-
mosomal stability.
RESULTS
Global Ptpn11E76K/+ mutation results in embryonic lethality
The pathogenic effects of the most common and most active 
Ptpn11  mutation  (Ptpn11E76K/+)  identified  in  JMML  and 
acute leukemias (Tartaglia et al., 2003, 2006; Kratz et al., 
2005; Aoki et al., 2008) have not been well characterized. To 
this end, we generated Ptpn11E76K knock-in mice (Fig. S1). 
In our gene-targeting strategy, a loxP-flanked neo cassette 
was inserted in intron 2 as the selective marker, which was 
followed by mutated exon 3 with E76K mutation. Intrigu-
ingly, we unexpectedly discovered that the inserted neo cas-
sette with a stop codon prevented expression of the targeted 
allele (Ptpn11E76K neo; Supplemental text and Fig. S2, C and D) 
and Ptpn11E76K neo/+ mice appeared healthy without gross ab-
normalities (Fig. S2 B). Upon deletion of neo by Cre DNA 
recombinase, the mutant allele (Ptpn11E76K) was reactivated, 
producing Shp2 E76K at the physiological level (Fig. S2 D 
catalytic site (Eck et al., 1996; Barford and Neel, 1998; Hof 
et al., 1998). Intriguingly, despite its direct function in pro-
tein dephosphorylation, Shp2 plays an overall positive role in 
transducing signals initiated from receptor and cytosolic ki-
nases (Neel et al., 2003; Tonks, 2006; Xu and Qu, 2008). 
This is particularly the case for the RAS–ERK pathway. The 
underlying  mechanism,  however,  remains  elusive.  Shp2 
interacts with several cell signaling intermediates. Of these 
partners, some are the targets of Shp2 enzymatic activity. 
However, none of the putative substrates identified to date 
can fully account for the overall positive signaling effects of 
Shp2 on the many biological processes with which it has 
been implicated. It appears that Shp2 functions in growth 
factor and cytokine signaling in both catalytically dependent 
and independent manners (Bennett et al., 1994; Li et al., 
1994; Yu et al., 2003).
Shp2 plays a vital role in embryogenesis and hemato-
poietic cell development. A null mutation of Ptpn11 resulted 
in periimplantation lethality in mice (Yang et al., 2006). Shp2- 
deficient blastocysts exhibited inner cell mass cell death and 
no trophoblast stem cells were developed in these embryos 
(Yang et al., 2006). Deletion of the N-SH2 domain generated 
a loss-of-function mutation in Shp2, which led to embryonic 
lethality at mid-gestation, with defects in mesodermal pat-
terning (Saxton et al., 1997). Chimeric mouse analyses dem-
onstrated that this loss-of-function mutation caused multiple 
developmental  defects  characterized  by  aberrant  skeletal 
structures and pathological changes in the epithelial system, 
which were clearly associated with diminished growth factor 
signaling (Qu et al., 1998, 1999). Shp2 plays a positive role in 
hematopoietic cell development. In vitro erythroid lineage 
differentiation of embryonic stem (ES) cells with the N-SH2 
deletion mutation of Shp2 was severely suppressed, and my-
eloid lineage differentiation was totally blocked (Qu et al., 
1997). Moreover, the contribution from these mutant ES 
cells to erythroid, myeloid, or lymphoid cells in the chimeric 
mice was undetectable (Qu et al., 1998, 2001). Most recent 
studies (Chan et al., 2011; Zhu et al., 2011) have confirmed 
that Shp2 is critical for the survival and maintenance of hema-
topoietic stem cells (HSCs) and immature progenitors. De-
pletion of Shp2 from adult mice resulted in rapid loss of HSCs 
and immature progenitors of all hematopoietic lineages.
Notably, germline and somatic mutations (heterozygous) 
in Ptpn11 (encoding Shp2) have been identified in 50% of 
the children with the developmental disorder Noonan syn-
drome (Tartaglia et al., 2001) and in 35% of the patients with 
juvenile myelomonocytic leukemia (JMML; Tartaglia et al., 
2003; Loh et al., 2004b), a childhood myeloproliferative dis-
order (MPD), both of which are associated with hyperactiva-
tion of the RAS–ERK pathway. Ptpn11 mutations found in 
Noonan syndrome are clustered in the PTP domain, whereas 
mutations seen in JMML are mainly localized in the N-SH2 
domain. These mutations result in amino acid changes at the 
interphase formed between N-SH2 and PTP domains, dis-
rupting the inhibitory intramolecular interaction, leading to 
hyperactivation of Shp2 catalytic activity (Tartaglia et al., 2003; JEM Vol. 208, No. 10 
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Shp2 phosphatase activity in the spleen lysates of pI-pC-treated 
knock-in (referred as to Ptpn11E76K/+/Mx1-Cre+) mice was 
indeed substantially increased (Fig. 2 B), in agreement with 
previous  observations  that  E76K  mutation  hyper-activates 
Shp2 (Tartaglia et al., 2003; Keilhack et al., 2005). Conse-
quently, Ptpn11E76K/+/Mx1-Cre+ mice uniformly developed 
MPD. These mice showed high white blood cell (WBC; 
mainly neutrophils) counts (Table S2). Splenomegaly (Fig. 2 C) 
and hepatomegaly (unpublished data) were also prominent. 
Histopathological examination revealed hyperproliferation of 
myeloid cells in both the spleen and BM (Fig. 2 D). FACS 
analyses confirmed excess myeloid expansion in the BM and 
spleen. Mac-1+/Gr-1+ mature myeloid cells were markedly 
increased in Ptpn11E76K/+/Mx1-Cre+ mice (Fig. 2 E). Consistent 
with  cell-autonomous  signaling  abnormalities  in  hemato-
poietic cells, myeloid progenitors from Ptpn11E76K/+/Mx1-Cre+ 
mice showed greatly increased responses to GM-CSF/IL-3 
(Fig. 2 F). Furthermore, these mutant progenitors yielded 
growth factor–independent colony formation in cytokine-
free medium (Fig. 2 F).
HSCs are hyperactivated by Ptpn11E76K/+ mutation
To further understand the mechanism by which Ptpn11E76K/+ 
mutation induces MPD, a clonal stem cell disorder, we as-
sessed the effects of Ptpn11E76K/+ mutation on HSCs. We 
found  that  LineageSca-1+c-Kit+  (LSK)  cells  that  are  en-
riched for HSCs were decreased by threefold in the BM of 
Ptpn11E76K/+/Mx1-Cre+ mice (Fig. 3 A and Table S3). LSK 
cells in the spleen, however, were greatly increased (Fig. 3 B), 
similar to those seen in PTEN-deficient mice (Yilmaz et al., 
2006; Zhang et al., 2006), reflecting extramedullary hemato-
poiesis in the mutant mice and potential microenvironmental 
impact on mutant stem cell homeostasis. Additional multi-
parameter FACS analyses (Tothova et al., 2007; Fleming et al., 
2008) showed that both long-term HSCs (LT-HSCs) and 
short-term HSCs (ST-HSCs; Fig. 3 C and Table S3) were 
significantly decreased in the BM of Ptpn11E76K/+ knock-in 
mice. Later stage progenitor populations, such as common 
myeloid progenitors (CMPs), granulocyte macrophage pro-
genitors (GMPs), and megakaryocyte erythroid progenitors 
(MEPs), were also decreased in mutant mice (Fig. 3 D and 
Table S3). Common lymphoid progenitors (CLPs), however, 
did not show significant changes (Fig. 3 D and Table S3). 
The results of phenotypic HSC analyses were verified by the 
greatly  decreased  repopulating  capabilities  of  mutant  BM 
cells in competitive repopulation assays (Fig. 3 E). Because 
peripheral WBCs and BM Mac-1+/Gr-1+ mature myeloid 
cells were increased in mutant mice, this rightward shift in 
the BM hematopoietic compartment suggests an accelerated 
activation  and  differentiation  of  mutant  stem/progenitor 
cells. In support of this notion, quiescent HSCs at the G0 
phase in mutant mice were decreased by twofold, whereas 
HSCs at the S and G2/M phases were doubled (Fig. 4 A). 
The decrease in the stem cell pool in the BM of mutant mice 
is not caused by any defects in cell survival. In fact, pro-
grammed cell death in Ptpn11E76K/+ mutant LSK cells was 
and Fig. 1 A). The mechanism for the inactivation of the tar-
geted allele is unclear. Importantly, this unexpected condi-
tional  allele  allows  expression  of  mutant  Shp2  under  the 
endogenous Ptpn11 promoter in an inducible manner, pre-
serving  temporal  and  spatial  transcriptional  regulation.  By 
crossing Ptpn11E76K neo/+ mice with global Cre transgenic   
(hypoxanthine-guanine  phosphoribosyltransferase  [HPRT]-Cre+) 
mice we found that induction of Shp2 E76K during early 
embryogenesis resulted in embryonic lethality at around em-
bryonic day 11.5 (E. 11.5; Fig. 1 B, Supplemental text, and 
Fig. S2 A) that appeared to be associated with aberrantly en-
hanced ERK activation (Fig. 1 C and Supplemental text).
Induced Ptpn11E76K/+ mutation in hematopoietic cells 
quickly leads to MPD with full penetrance
To determine the pathogenic effects of somatic Ptpn11E76K/+ 
mutation on hematopoietic cell development, we generated 
Ptpn11E76K neo/+/Mx1-Cre+ mice by crossing Ptpn11E76K neo/+ 
mice with Mx1-Cre transgenic mice that express Cre in pan-
hematopoietic cells in response to polyinosinic-polycytidylic 
acid  (pI-pC)  treatment  (Kühn  et  al.,  1995).  4-wk-old 
Ptpn11E76K neo/+/Mx1-Cre+ mice were treated with pI-pC to 
induce Cre expression. Neo deletion efficiency in the BM cells 
and splenocytes of these mice was nearly complete (Fig. 2 A), 
and mutant Shp2 was expressed at a level comparable to   
that of WT Shp2 in Ptpn11+/+/Mx1-Cre+ mice (Fig. 2 B). 
Figure 1.  Global Ptpn11E76K/+ mutation results in embryonic  
lethality. (A) Schematic diagram of the Ptpn11E76K neo conditional allele. The  
insertion of the neo cassette with a stop codon in intron 2 disrupts the 
targeted allele. This allele is reactivated and expresses Shp2 E76K upon 
deletion of the neo cassette by Cre DNA recombinase. (B) Representative 
E. 9.5 and E. 11.5 embryos of Ptpn11+/+/HPRT-Cre+ and Ptpn11E76K/+/HPRT-
Cre+ genotypes produced from intercrosses between Ptpn11E76K neo/+ and 
HPRT-Cre+ mice. Bars, 1 mm. (C) Whole mounts of E. 10.5 embryos pro-
duced from intercrosses between Ptpn11E76K neo/+ and HPRT-Cre+ mice 
were immunostained with anti–phospho-ERK antibody following stan-
dard procedures. Front nasal processes, limb buds, and somites of 
Ptpn11E76K/+ embryos are indicated by arrows. Bar, 1 mm.1980 Oncogenic Ptpn11 in leukemogenesis | Xu et al.
(Yilmaz et al., 2006; 
Guo  et  al.,  2008) 
were  substantially 
increased (Fig. 5 C). 
Mac-1+/c-Kit+ my-
eloblasts (Cozzio et al., 2003; So et al., 2003; Rosenbauer   
et al., 2004; Kirstetter et al., 2008) were >20% in the BM 
(Fig. S3 A). In the mice with T cell acute lymphoblastic leu-
kemia/lymphoma (T-ALL) (Fig. 5 D), 50–70% of BM cells 
were CD4+/CD8+ and CD44+ cells, indicative of a T cell 
differentiation block near the pro–T stage. A substantial por-
tion of these cells were also positive for c-Kit (Fig. 5 D), an 
early stage stem/progenitor cell marker. T lymphoma cells 
also expressed the myeloid marker Mac-1 (Fig. S3 B), which 
is consistent with lineage infidelity/promiscuity of leukemia 
cells (Smith et al., 1983). In addition, CD3+/c-Kit+ cells, de-
fined as T-ALL LSCs in PTEN knockout mice (Yilmaz et al., 
2006; Guo et al., 2008), were detected within the blast com-
partment (Fig. S3 A). In the mice that progressed to B-ALL, 
60–70% of BM cells were B220+ (Fig. 5 E). Of these B220+ 
cells, 70–80% cells were also positive for an early B lineage 
marker CD43 and the stem cell marker Sca-1, but negative 
for the mature B cell marker IgM, indicating a B lineage 
decreased (Fig. 4 B). More likely, aberrant activation of mu-
tant stem cells eventually led to the depletion of the stem cell 
population  caused  by  exhaustion  of  the  reserve  capacity. 
HSC activities, such as cycling and survival, are tightly con-
trolled by cytokines and growth factors. Assessment of cell 
signaling activities confirmed that in response to stem cell 
factor (SCF) stimulation, activation of ERK (Fig. 4 C) and 
AKT (Fig. 4 D) kinases in mutant LSK cells was greatly en-
hanced compared with that in control cells.
Various types of leukemias are evolved in Ptpn11E76K/+ mice
Strikingly, after 12–32 wk of chronic MPD where differenti-
ation/maturation  of  myeloid  cells  was  essentially  normal, 
Ptpn11E76K/+  knock-in  mice  progressed  to  the  accelerated 
phase, resembling acute leukemias where there was profound 
impairment of hematopoietic differentiation. These mice 
presented  with  extremely  high  WBC  counts,  progressive 
anemia, and leukemia infiltration in nonhematopoietic or-
gans, and then became moribund (Fig. 5, A and B). Intrigu-
ingly,  various  types  of  leukemias  were  evolved,  although   
the mutant mice initially manifested MPD (Fig. 5, A and B;   
Table S1 ; and Fig. S3 A). In the mice that progressed to AML, 
Mac-1+/Gr-1low, or Mac-1+/Gr-1, poorly differentiated cells 
Figure 2.  Ptpn11E76K/+ mutation in  
hematopoietic cells initially induces MPD 
with full penetrance. (A) 4-wk-old 
Ptpn11E76K neo/+/Mx1-Cre+ and Ptpn11E76K neo/+/
Mx1-Cre mice were treated by i.p. injection 
of a total of 5 doses of pI-pC acid (350 µg/
mouse) administered every other day over  
10 d. 4 wk after pI-pC treatment, genomic DNA 
was extracted from the BM and spleen. PCR 
detection of the neo segment was performed 
using the primers shown in the diagram  
(bottom). (B) Spleen lysates prepared from 
Ptpn11+/+/Mx1-Cre+, Ptpn11E76K/+/Mx1-Cre+, 
and Ptpn11E76K neo/+/Mx1-Cre mice 6 wk after 
pI-pC treatment were immunoprecipitated 
with anti-Shp2 antibody. Immune complexes 
were subjected to the phosphatase assay 
using 4-nitrophenyl phosphate disodium salt 
hexahydrate as the substrate following stan-
dard procedures. Shp2 levels in the tissue 
lysates were examined by anti-Shp2 immuno-
blotting. Blots were stripped and reprobed 
with -actin antibody to check protein load-
ing. (C) Mouse spleen weight was quantified 
6–8 wk after pI-pC treatment (n = 8 per 
group). Bar, 5 mm. (D) Spleens and femurs 
isolated from Ptpn11E76K/+/Mx1-Cre+ and 
Ptpn11+/+/Mx1-Cre+ mice 8 wk after pI-pC 
injection were processed for histopathological 
examination (Hematoxylin and eosin staining). 
Bars, 50 µm. (E) BM cells and splenocytes 
isolated from Ptpn11E76K/+/Mx1-Cre+ and 
Ptpn11+/+/Mx1-Cre+ littermates (n = 5 per 
group) were assayed for Mac-1+/Gr-1+ cells 
by FACS analyses 8 wk after pI-pC injection. 
(F) BM cells (2 × 104/ml) harvested from 
Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/Mx1-
Cre+ littermates (n = 3 per group) were  
assessed by myeloid colony assays 6 wk after 
pI-pC injection.JEM Vol. 208, No. 10 
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Non–lineage-/stage-specific effects of Ptpn11E76K/+ 
mutation on LSC development
To determine at what stage in hematopoiesis initial LSCs 
were derived in Ptpn11E76K/+ knock-in mice during the pro-
gression from MPD to full blown leukemias, we purified 
HSC-enriched LSK cells from Ptpn11E76K/+/Mx1-Cre+ mice 
in the MPD stage (8–10 wk after pI-pC treatment), mixed 
these cells with 105 lineage+ cells (to radioprotect recipients), 
and transplanted them into BoyJ mice. As shown in Fig. 6 A, 
all of Ptpn11E76K/+ mutant LSK cell transplants developed 
MPD;  40%  of  them  subsequently  transformed  into  acute 
leukemias. These data suggest that the leukemogenic effects 
of Ptpn11E76K/+ mutation are cell intrinsic and that LSCs can 
be  developed  from  early  stage  stem  cells.  To  further  test 
whether Ptpn11E76K/+ mutation can also cause leukemias in lin-
eage-committed progenitors, we generated lineage-specific 
knock-in  mice,  i.e.,  Ptpn11E76K/+/LysM-Cre+  (in  GMPs), 
Ptpn11E76K/+/LCK-Cre+ (in CD4/CD8 stage T cells), and 
maturation arrest at around the pro–B stage. Pathological 
examination revealed leukemic cell invasion into hemato-
poietic and nonhematopoietic organs (Fig. 5 F). This was 
further characterized by a large number of chloroacetate- 
esterase-positive  myeloid  leukemic  cells  in  the  BM  and 
other organs in AML and large numbers of terminal deoxy-
nucleotidyl  transferase  (TdT)-positive  lymphoid  blasts 
throughout the BM and other organs in T-ALL (Fig. 5 G). 
Transplantation of BM cells from terminally ill mice repro-
duced leukemias of the same type in recipient mice (Fig. 5 H). 
In  addition,  limiting  dilution  transplantation  experiments 
revealed that the oncogenic Ptpn11-induced hematologic 
malignancies were prorogated by LSCs and that the fre-
quency of LSCs in AML was low, whereas the frequencies 
of LSCs in T-ALL and B-ALL were very high (Fig. 5 H). 
This suggests that concentrations of LSCs vary depending 
on leukemia types, although they were initiated by the same 
oncogene Ptpn11E76K.
Figure 3.  Accelerated hematopoietic cell differentiation in 
Ptpn11E76K/+ knock-in mice during the MPD phase. BM cells freshly 
harvested from Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/Mx1-Cre+ litter-
mates 8 wk after pI-pC treatment were assayed by multiparameter FACS 
analyses to determine frequencies of hematopoietic cell populations of 
various stages and lineages. (A) Frequency of HSC-enriched LSK cells in 
the BM (n = 8 per group). (B) Frequency of LSK cells in the spleen (n = 6 
per group). (C) Frequencies of LT-HSCs and ST-HSCs in the BM (n = 4 per 
group). (D) Frequencies of CMP, GMP, and MEP populations in the BM  
(n = 7 per group). (E) BM cells (test cells) harvested from pI-pC–treated 
Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/Mx1-Cre+ littermates (CD45.2+) 
were transplanted with the same number of BoyJ (CD45.1+) BM cells 
(competitor cells) into lethally irradiated BoyJ (CD45.1+) recipients (n = 7 
per group). Test cell reconstitution was determined 8, 12, 16, and 24 wk 
after transplantation by FACS analyses of peripheral blood leukocytes.
Figure 4.  HSCs are hyperactivated by Ptpn11E76K/+ mutation.  
(A) BM cells freshly harvested from Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/
Mx1-Cre+ mice (n = 5 per group) were assayed by multiparameter FACS 
analyses to determine cell cycle status of HSC-enriched LSK cells. Per-
centages of LSK cells at G0, G1, and S/G2/M phases identified based on 
Pyronin Y and Hoechst staining profiles were quantified. (B) BM cells from 
Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/Mx1-Cre+ mice (n = 4 per group) 
were analyzed by multiparameter FACS analyses to determine apoptotic 
cells (Annexin V+ cells) in the LSK population. (C and D) Lineage BM cells 
from Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/Mx1-Cre+ mice (n = 3 per 
group) were purified and starved for 1 h in IMDM medium. Cells were 
then stimulated with SCF (50 ng/ml) for 5 min, fixed, permeabilized, and 
stained with antibodies against Sca-1, c-Kit, and phospho-ERK or  
phospho-AKT. Percentages of the cells stained positive for phospho-ERK (C) or 
phospho-AKT (D) in the gated LSK population were measured by multi-
parameter FACS analyses.1982 Oncogenic Ptpn11 in leukemogenesis | Xu et al.
mice invariably manifested MPD as early as at the time when 
the mice were weaned because of apparently enhanced my-
eloid cell proliferation and differentiation (Fig. 6 A). In contrast, 
Ptpn11E76K/+/CD19-Cre+ (in pro–/pre–B stage B cells) mice 
using LysM-Cre, LCK-Cre, and CD19-Cre transgenic mice 
(Jude  et  al.,  2007),  respectively.  Ptpn11E76K/+/LysM-Cre+ 
Figure 5.  Various leukemias with differen-
tiation block are subsequently evolved in 
Ptpn11E76K/+ mice. (A) Kaplan–Meier survival 
curve in a cohort of Ptpn11E76K/+/Mx1-Cre+ mice 
(n = 31) and a cohort of Ptpn11+/+/Mx1-Cre+  
(n = 72) mice after pI-pC treatment. Disease dis-
tribution in the 27 moribund/dead Ptpn11E76K/+/
Mx1-Cre+ mice is shown on the bottom.  
(B) A representative Ptpn11E76K/+ knock-in mouse 
with thymic lymphoma is shown on the left. 
Peripheral blood smear, lung, and liver from  
another leukemic Ptpn11E76K/+ knock-in mouse 
are shown on the right. Bars on blood smear and 
organ pictures represent 10 µm and 10 mm, 
respectively. (C) BM and peripheral blood cells 
harvested from terminally ill Ptpn11E76K/+/Mx1-
Cre+ mice and Ptpn11+/+/Mx1-Cre+ control mice 
were immunostained with antibodies against 
CD45, Mac-1, Gr-1, and c-Kit. The SSCmedCD45high 
population was subfractioned according to c-Kit 
and Mac-1 expressions to determine Mac-1+/c-
Kit+ blasts. (D) BM cells collected from moribund 
Ptpn11E76K/+/Mx1-Cre+ mice and Ptpn11+/+/Mx1-
Cre+ control mice were immunostained with 
antibodies against CD45, CD4, CD8, CD44, and  
c-Kit. The side scatter (SSC)lowCD45high/med blast 
population was subfractioned according to CD44 
and c-Kit or CD4 and CD8 expressions to deter-
mine CD4+/CD8+ cells and CD44+/c-Kit+ blasts.  
(E) BM cells and splenocytes collected from mori-
bund Ptpn11E76K/+/Mx1-Cre+ mice and Ptpn11+/+/
Mx1-Cre+ control mice were immunostained with 
antibodies against CD45, B220, IgM, and Sca-1. 
B220+/Sca-1+ cells, B220+/IgM+ cells, and the 
blast (SSClowCD45low) population were shown.  
(F) Tissues harvested from terminally diseased 
Ptpn11E76K/+/Mx1-Cre+ mice and Ptpn11+/+/Mx1-
Cre+ controls were processed for histopathologi-
cal examination (hematoxylin and eosin staining). 
Bars on 1000× and 100× pictures represent 20 
and 200 µm, respectively. (G) BM, spleen, and liver 
harvested from a Ptpn11E76K/+/Mx1-Cre+ mouse 
that had progressed to AML were processed for 
chloroacetate esterase staining. BM, thymus, and 
liver harvested from a Ptpn11E76K/+/Mx1-Cre+ 
mouse in which T-ALL was evolved were pro-
cessed for terminal deoxynucleotidyl transferase 
(TdT) staining. Bars, 50 µm. (H) BM cells collected 
from Ptpn11E76K/+/Mx1-Cre+ mice with AML,  
T-ALL, or B-ALL were transplanted into sublethally 
irradiated BoyJ (600 rads) or NOD-SCID (200 rads) 
mice at the indicated cell doses. Recipient mice 
were monitored on a daily basis for 100 d. 
Moribund mice were sacrificed. Diagnosis for 
each mouse was made by multiparameter FACS 
analyses, blood smear, and tissue histopathologi-
cal examinations as described.JEM Vol. 208, No. 10 
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knock-in mice were also transplantable in primary and secon-
dary recipient mice (Fig. 6 C). The fact that Ptpn11E76K/+ mu-
tation causes leukemias in lineage progenitors strongly suggests 
that preexisting self-renewal program in target cells is not re-
quired for Ptpn11E76K/+ mutation to induce LSC development.
Ptpn11E76K/+ mutation also induces centrosome 
amplification and chromosomal instability
During  the  MPD-to-leukemia  progression  in  Ptpn11E76K/+/
Mx1-Cre+ mice, additional genetic alterations necessary for ma-
lignant transformation might have acquired. Indeed, spectral 
karyotype analyses for T-ALL cells showed gain or loss of whole 
chromosomes, or chromosomal structural (translocations and 
deletion) changes (Fig. 7 A). Common abnormalities across 
multiple karyotypes from each mouse additionally suggest   
that the malignancies that evolved were clonal or oligoclonal.   
Genomic  abnormalities  are  thought  to  arise  from  enhanced   
cell proliferation and differentiation. However, T and B cell   
development was normal in Ptpn11E76K/+/LCK-Cre+ and 
Ptpn11E76K/+/CD19-Cre+ mice before the onset of T-ALL and 
B-ALL (Fig. S4). The non–lineage-specific effects of Ptpn11E76K/+ 
mutation on hematopoietic cell transformation prompted us to 
test for a potential general impact of this mutation on genomic 
stability independent of cell growth rate. We examined karyo-
types of mutant hematopoietic cells before acute leukemia trans-
formation. BM cells (nonmegakaryocytes) and splenocytes from 
Ptpn11E76K/+/Mx1-Cre+ mice during the MPD phase readily 
displayed aneuploidy, a state of having abnormal numbers of 
chromosomes (Fig. 7 B). Moreover, this genomic instability in 
purified mutant LSK, LK (Lineagec-Kit+, early myeloid pro-
genitors), GMP, and whole BM cells was accelerated by in vitro 
culture stress (Fig. 7 C). Genome integrity is maintained by vari-
ous cellular surveillance mechanisms (Kastan and Bartek, 2004). 
Because Ptpn11E76K/+ mutant cells overall displayed increased 
aneuploidy that is known to be associated with defects in mito-
sis, we surveyed centrosomes in hematopoietic cells and found 
marked centrosome amplification in preleukemic Ptpn11E76K/+/
Mx1-Cre+ mice. Percentages of the cells with ≥3 centrosomes in 
fresh (Fig. 7 D and Fig. S5 A) or cultured (Fig. 7 E) mutant LK, 
GMP, and unsorted BM cells (nonmegakaryocytes) were signif-
icantly increased, although centrosome amplification in mutant 
LSK cells was not significant. More interestingly, during the 
course of these experiments, we surprisingly found that Shp2 
(encoded by Ptpn11) was distributed to centrosomes. Shp2 co-
localized with -tubulin, a centrosome-specific structural pro-
tein (Fig. 7 F). Intriguingly, in Ptpn11E76K/+ hematopoietic cells 
(at both MPD and acute leukemia phases) with multiple centro-
somes, Shp2 was only localized to part, but not all amplified 
centrosomes (Fig. 7 F and Fig. S5 B), indicating that centrosome 
amplification and genomic instability in the mutant cells are   
associated at least in part with Shp2 E76K mutation.
DISCUSSION
Hematopoietic  cell  development  and  function  are  tightly 
controlled by environmental cues, such as cytokines and growth 
factors.  Dysregulation  of  cytokine/growth  factor  signaling 
no T or B cell developmental abnormalities were detected in 
Ptpn11E76K/+/LCK-Cre+ and Ptpn11E76K/+/CD19-Cre+ mice 
during the first 4 mo of life (Fig. S4). Surprisingly, 40% of 
Ptpn11E76K/+/LysM-Cre+, 53% of Ptpn11E76K/+/LCK-Cre+, and 
44%  of  Ptpn11E76K/+/CD19-Cre+  mice  subsequently  devel-
oped AML, T-ALL, and B-ALL, respectively (Fig. 6, A and B). 
Similar  to  the  acute  leukemias  in  Ptpn11E76K/+/Mx1-Cre+ 
mice, AML, T-ALL, and B-ALL developed in lineage-specific 
Figure 6.  Non–lineage/stage-specific effects of Ptpn11E76K/+ mu-
tation on malignant transformation of hematopoietic cells. (A) LSK 
cells were purified from Ptpn11E76K/+/Mx1-Cre+ mice at the MPD stage  
(8 wk after pI-pC treatment). These cells (2.5 × 103/per mouse) were mixed 
with 105 lineage+ cells and then transplanted into lethally irradiated 
(1,100 rads) BoyJ mice. Recipient mice were monitored on a daily basis  
for 12 mo. Leukemias developed in Ptpn11E76K/+/LysM-Cre+, Ptpn11E76K/+/ 
LCK-Cre+, and Ptpn11E76K/+/CD19-Cre+ mice were summarized. (B) Kaplan– 
Meier survival curves of lineage-specific Ptpn11E76K/+ knock-in mice. 
Ptpn11E76K neo/+ mice were used to cross LysM-Cre, LCK-Cre, or CD19-Cre 
transgenic mice of C57BL6 genetic background (The Jackson Laboratory) 
to generate Ptpn11E76K/+/LysM-Cre+ (n = 10), Ptpn11E76K/+/LCK-Cre+ (n = 15), 
and Ptpn11E76K/+/CD19-Cre+ (n = 9) mice, respectively. These mice and 
three control lines of mice (n = 15 each per group) were monitored for  
12 mo. Moribund mice were euthanized and diagnosed as described.  
(C) BM cells collected from moribund Ptpn11E76K neo/+/LysM-Cre+, Ptpn11E76K/+/
LCK-Cre+, and Ptpn11E76K/+/CD19-Cre+ mice with AML (2 × 106 cells),  
T-ALL (103 cells), or B-ALL (104 cells) were transplanted into sublethally 
irradiated BoyJ (600 rads) mice. BM cells harvested from moribund recipi-
ent mice with leukemias were transplanted into sublethally irradiated 
secondary recipients at the same doses as described.1984 Oncogenic Ptpn11 in leukemogenesis | Xu et al.
are also aberrantly activated in Ptpn11E76K/+ knock-in mice. 
The percentage of stem cells (LSK cells) in G1 or S/G2/M 
phases is increased in these animals, whereas quiescent stem 
cells at the G0 phase are decreased (Fig. 4 A), and growth fac-
tor (SCF)–induced signaling activities are much stronger in 
Ptpn11E76K/+ LSK cells (Fig. 4, C and D). Thus, the MPD 
phenotypes caused by Ptpn11E76K/+ mutation are largely at-
tributed to the enhanced cytokine/growth factor signaling in 
stem cells and myeloid progenitors. Because Ptpn11E76K/+ LSK 
cells reproduce MPD in recipients (Fig. 6 A), whereas CMPs 
and CLPs purified from Ptpn11E76K/+ mice with MPD do not 
generate any diseases in recipients (unpublished data), it ap-
pears that MPD can only be initiated when Ptpn11E76K/+ mu-
tation occurs in HSCs but not in lineage progenitors lacking 
may result in hematologic disorders. Shp2 phosphatase plays 
a positive role in the signal transduction of multiple cytokines 
and growth factors, although the underlying mechanisms are 
still unclear (Neel et al., 2003; Tonks, 2006; Xu and Qu, 
2008). Shp2 functions in cytokine (IL-3) signaling in both 
catalytically dependent and independent manners (Yu et al., 
2003). The E76K mutation in the N-SH2 domain of Shp2 
enhances IL-3 signaling through both elevated catalytic ac-
tivity and increased binding to signaling partners (Yu et al., 
2006). Myeloid progenitors in Ptpn11E76K/+ knock-in mice 
are hypersensitive to GM-CSF and IL-3 (Fig. 2 F), which is 
reminiscent of JMML (Birnbaum et al., 2000; Zhang et al., 
1998). This is obviously caused by the enhancing effect of 
Shp2 E76K mutant on cytokine signaling. Notably, stem cells 
Figure 7.  Centrosome amplification and 
chromosomal instability in Ptpn11E76K/+ 
hematopoietic cells. (A) T-ALL tumor cells 
from pI-pC–treated Ptpn11E76K/+/Mx1-Cre+ 
mice were examined by spectral karyotype 
analyses. 12 metaphase spreads were exam-
ined for each sample. A representative result 
is shown. (B) BM cells and splenocytes freshly 
isolated from Ptpn11E76K/+/Mx1-Cre+ mice at 
the MPD stage and Ptpn11+/+/Mx1-Cre+ con-
trol mice (6–8 wk after pI-pC treatment) were 
assayed by karyotyping analyses. Cells (non-
megakaryocytes) with more or <40 chromo-
somes were counted as aneuploid cells. 
Results shown are a summary of the data 
obtained from five mice in each group. (C) LSK 
cells, LK cells, and GMPs were sorted from the 
BM of Ptpn11E76K/+/Mx1-Cre+ mice at the MPD 
stage and Ptpn11+/+/Mx1-Cre+ control mice. 
Purified cells, along with whole BM cells, were 
cultured in IMDM medium containing Tpo  
(20 ng/ml), FIt3 ligand (50 ng/ml), SCF (50 ng/ml), 
IL-3 (20 ng/ml), IL-6 (20 ng/ml), and 10% FBS 
(for LSK cells) or SCF (50 ng/ml), IL-3 (20 ng/ml), 
IL-6 (20 ng/ml), and 10% FBS (for other cell 
types) for 60 h (LSK and LK cells), 48 h (BM 
cells), and 16 h (GMPs) hours. Cells (non-
megakaryocytes) were then examined by 
karyotyping analyses, as described. (D) LSK 
cells, LK cells, and GMPs were sorted from the 
BM of Ptpn11E76K/+/Mx1-Cre+ mice at the MPD 
stage and Ptpn11+/+/Mx1-Cre+ control mice. 
Purified cells along with whole BM cells were 
immunostained with anti–-tubulin antibody. 
Centrosomes were then examined under a 
fluorescence microscope. For LSK cells, at least 
100 cells were surveyed in each experiment. 
For the other cell types, at least 300 cells were 
examined in each experiment. Results shown 
are mean ± SEM of three independent experi-
ments. (E) Purified LSK cells, LK cells, and unsorted BM cells were cultured in the medium (as described) for 48 h. Cells were then immunostained with 
anti–-tubulin antibody. Centrosomes were examined under a fluorescence microscope. Data shown are mean ± SEM of three independent experiments. 
(F) LK cells purified from Ptpn11E76K/+/Mx1-Cre+ mice at the MPD stage and Ptpn11+/+/Mx1-Cre+ control mice (top), and BM cells from Ptpn11E76K/+/Mx1-
Cre+ mice with B-ALL (bottom) were immunostained with anti–-tubulin and Shp2 antibodies. Nuclei were counterstained with DAPI. The images were 
captured and analyzed using a laser-scanning confocal microscope. Bars, 5 µm.JEM Vol. 208, No. 10 
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Ptpn11E76K/+/Mx1-Cre+ mice (Fig. 7, B and D). Neverthe-
less, the detailed molecular mechanisms by which Shp2 E76K 
mutation causes centrosome amplification remain to be fur-
ther determined. Also, it is important to verify whether aneu-
ploidy  is  a  characteristic  of  Ptpn11-mutation-associated 
leukemias in humans and whether aneuploidy in these leuke-
mias correlates with centrosome amplification. Shp2 is only 
localized  to  some,  but  not  all,  amplified  centrosomes  in 
Ptpn11E76K/+ cells in both MPD and acute leukemia phases 
(Fig. 7 F and Fig. S5 B), raising the possibility that displace-
ment of Shp2 from centrosomes may be associated with the 
centrosome amplification although it is uncertain how this 
displacement occurs and how it disturbs centrosome func-
tions. Clearly, identification of Shp2 substrates or interacting 
proteins in centrosomes may shed the light on detailed mech-
anisms. As other Shp2 GOF mutations (D61G and D61Y) 
only induce MPD (Araki et al., 2004; Chan et al., 2009; Xu 
et al., 2010) and the E76K mutation is more potent than 
D61G/Y mutations in enhancing the catalytic activity of Shp2 
(Tartaglia et al., 2003; Keilhack et al., 2005), the role of Shp2 
GOF mutations in inducing additional genetic abnormalities 
driving LSC development seems to be attributable to the en-
hanced catalytic activity of mutant Shp2. Finally, our finding 
that Ptpn11E76K/+ mutation is sufficient to induce acute leuke-
mias implicates that Ptpn11E76K/+ mutation might be the initi-
ating genetic lesion in pediatric B-ALL and AML that have 
Ptpn11E76K/+ mutation, highlighting a broader causative role 
for Ptpn11 GOF mutations in the pathogenesis of childhood 
leukemias. Accordingly, Shp2 may be a useful therapeutic tar-
get for the treatment of these acute leukemias and for the pre-
vention of malignant transformation in JMML.
MATERIALS AND METHODS
Generation of Ptpn11E76K knock-in mice. Ptpn11 allele was targeted by 
homologous recombination. The targeting vector was constructed using the 
recombineering technique, as previously described (Liu et al., 2003). In brief, 
a mini–targeting vector with a loxP-flanked neo cassette and the mutation 
GAA (E) → AAA (K) at the amino acid 76 encoding position in exon 3 of 
Ptpn11 was first generated. This mini vector was then used to construct the 
targeting vector. The targeting vector was linearized and electroporated into 
D1 mouse ES cells derived from F1 hybrid blastocysts of 129S6 x C57BL/6J. 
G418-resistant ES cell clones were isolated and screened for homologous re-
combination by nested PCR using primers outside the construct paired with 
primers inside the neo cassette (Fig. S1 A). Positive clones were further con-
firmed by PCR genotyping (Fig. S1 B) and sequencing for the mutation 
(GAA → AAA) in genomic DNA (Fig. S1 C). Two individual ES cell clones, 
containing a correctly targeted Ptpn11 allele, were used to generate chimeric 
mice. Germline transmitted chimeric mice were obtained and used to cross 
C57BL6/J  mice  to  generate  heterozygous  mice  with  the  neo  cassette 
(Ptpn11E76K neo/+). E76K mutation in F1 Ptpn11E76K neo/+ mice was verified by 
sequencing the targeted site of genomic DNA. These mice were backcrossed 
with C57BL6/J mice for 3–6 generations for experiments. Mice used for 
transplantation analyses were 8th to 10th generation backcross to C57BL6/J 
background. No differences in the two lines of mutant mice derived from the 
original two ES cell clones were observed. All mice were kept under specific 
pathogen–free conditions in the Animal Resources Center at Case Western 
Reserve University. All animal procedures complied with the National Insti-
tutes of Health Guidelines for the Care and Use of Laboratory Animals and 
were approved by the Institutional Animal Care and Use Committee.
self-renewal  capabilities,  although  persistent  induction  of 
Ptpn11E76K/+  mutation  in  myeloid  progenitors  also  causes 
overproduction of myeloid cells in Ptpn11E76K/+/LysM-Cre+ 
mice (Fig. 6 A).
It is interesting that Ptpn11E76K/+ mutation causes acute 
leukemias in both stem cells and lineage-committed progeni-
tors. Ptpn11E76K/+ mutation in pan-hematopoietic cells serves 
as the first hit, resulting in MPD initially. During this chronic 
phase, apparently, additional genetic alterations are evoked, 
which  then  cooperatively  transform  hematopoietic  cells, 
leading to the onset and full development of acute leukemias. 
Remarkably, Ptpn11E76K/+ mutation also causes acute leuke-
mias in lineage-committed progenitors (Fig. 6). Progenitors 
do not possess self-renewal capabilities, which is a character-
istic feature of LSCs, thus a preexisting self-renewal program 
does not seem to be required for Ptpn11E76K/+ mutation to 
transform the target cells to LSCs. Likely, it is the additional 
genetic alterations subsequently evoked that reprogram these 
cells, conferring self-renewal capabilities to sustain leukemia 
growth. Indeed, centrosome amplification and aneuploidy 
that are associated with genetic alterations are detected much 
earlier than the emergence of acute leukemias in Ptpn11E76K/+ 
knock-in mice (Fig. 7, B and D). The fact that Ptpn11E76K/+ 
mutation has non–lineage/stage-specific effects on the devel-
opment of LSCs suggests that Ptpn11E76K mutation has a cell-
transforming capability.
Genetic abnormalities are thought to arise from enhanced 
cell proliferation and differentiation. Uncontrolled activation 
of Ptpn11E76K/+ stem cells or myeloid progenitors may lead to 
acquisition of additional genetic alterations. Thus, it is not un-
expected  that  MPD  subsequently  progress  to  AML  in 
Ptpn11E76K/+/MX1-Cre+ mice. However, T-ALL and B-ALL 
are also evolved in these animals. Furthermore, persistent in-
duction of Ptpn11E76K/+ mutation in T and B lymphoid pro-
genitors  in  lineage-specific  knock-in  mice  also  results  in 
T-ALL and B-ALL, respectively (Fig. 6). Because no T or B 
lymphoid developmental abnormalities are detected before the 
onset of T-ALL and B-ALL in these mice (Fig. S4), these ob-
servations argue that the acquisition of the secondary genetic 
lesions in T and B progenitors conferring self-renewal proper-
ties is not related to uncontrolled cell proliferation/differentia-
tion. Rather, the secondary genetic abnormalities are evoked 
by Ptpn11E76K/+ mutation through other mechanisms.
Ptpn11E76K/+ mutation may induce genetic alterations by 
disturbing centrosome function among other mechanisms. In 
support of this hypothesis, Shp2 is found to be distributed to 
centrosomes that play a critical role in chromosome segrega-
tion during mitosis (Draviam et al., 2004; Ruchaud et al., 
2007), and centrosomes are amplified in Ptpn11E76K/+ mutant 
hematopoietic cells (Fig. 7, D and F). As centrosome amplifi-
cation is known to result in aberrant multipolar mitosis and 
missegregation of chromosomes, leading to aneuploidy and 
proneness to cancer (Draviam et al., 2004; Ruchaud et al., 2007), 
the overall correlation of centrosome amplification with aneu-
ploidy in Ptpn11E76K/+ hematopoietic cells indicates that cen-
trosome amplification is likely responsible for aneuploidy in 1986 Oncogenic Ptpn11 in leukemogenesis | Xu et al.
Spectral Karyotyping (SKY) SD300VDS workstation equipped with SKY 
View software (Applied Spectral Imaging).
Immunostaining and confocal microscopy. Freshly isolated or cultured 
hematopoietic cells were spun onto microscope slides by cytospin, fixed in 
100% methanol at 20°C for 10 min, permeabilized with 0.1% Triton   
X-100 in PBS, and blocked with 2% BSA in PBS at room temperature for   
1 h. Cells were incubated with primary antibodies at room temperature for 
1 h or 4°C overnight. The cells were then washed three times with PBS and 
incubated with Alexa Fluor 488– or Alexa Fluor 568–conjugated secondary 
antibodies for 1 h. Nuclei were counterstained with DAPI. After washing, 
slides were mounted by coverslips. All confocal images were acquired using   
an LSM 510 inverted laser-scanning confocal microscope (Carl Zeiss, Inc.).   
Images were analyzed with MetaMorph software. Whole-mount phospho-Erk   
immunostaining was performed as previously described (Corson et al., 2003).
Statistical analysis. All studies were repeated at least twice with consistent 
results and with a minimum of three mice per group, although typically 
more (as indicated in figure legends). Data are presented as mean ± SEM. 
Statistical significance was determined using unpaired two-tailed Student’s   
t test. P-values <0.05 were considered to be significant.
Online supplemental material. Fig. S1 shows the gene targeting strategy, 
verification of the targeted Ptpn11 allele, and heterozygous E76K mutation 
in chimeric mice. Fig. S2 shows that global Ptpn11E76K/+ mutation results in 
embryonic lethality and that insertion of neo in intron 2 of the targeted 
Ptpn11 allele prevents expression of Shp2 E76K. Fig. S3 shows disease pro-
gression in Ptpn11E76K/+ knock-in mice. Fig. S4 shows that Ptpn11E76K/+ 
mutation in T or B lymphoid progenitors does not significantly disturb T or 
B cell development. Fig. S5 shows centrosome amplification in Ptpn11E76K/+ 
BM cells and that Shp2 is localized to part, but not all, of amplified centro-
somes in these cells. The Supplemental text describes the pathogenic effects 
of Ptpn11E76K/+ mutation on embryonic development and the inducible   
nature of the Ptpn11E76K allele created. Table S1 summarizes the features of 
T-ALL,  B-ALL,  AML,  MPD  in  acceleration,  and  MPD  developed  in 
Ptpn11E76K/+ knock-in mice. Table S2 shows peripheral blood cell counts of 
Ptpn11E76K knock-in and control mice. Table S3 shows the absolute num-
bers of HSCs and progenitors of various stages in the BM from Ptpn11E76K 
knock-in and control mice. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20110450/DC1.
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Flow cytometric analysis and cell sorting. Multiparameter FACS analy-
sis was performed to determine populations of HSC-enriched LineageSca-1+ 
c-Kit+ (LSK) cells, LT-HSCs (LineageSca-1+c-Kit+Flk2CD34), ST-HSCs 
(LineageSca-1+c-Kit+Flk2CD34+),  and  lineage  progenitors,  such  as 
CMPs (Lineagec-Kit+Sca-1CD16/32medCD34+), CLPs (Lineagec-Kitlow 
Sca-1lowCD127+), GMPs (Lineagec-Kit+Sca-1CD16/32highCD34+), and 
MEPs  (Lineagec-Kit+Sca-1CD16/32med/lowCD34).  BM  cells  freshly   
harvested from femurs and tibias were first stained with anti–Flk2-biotin   
and  subsequently  stained  with  antibodies  labeled  with  various  fluoro-
chromes: streptavidin-APC-Cy7, c-Kit-APC, Sca-1-PE, CD34-Pacific blue, 
CD16/32-PE-Cy7, and CD127 (IL-7R)-PE-Cy5 (eBioscience); and FITC-
labeled antibodies for lineage markers Mac-1, Gr-1, Ter119, CD4, CD8a, 
CD3e, and B220 (BD). Specific cell populations were gated based on immuno-
phenotypes for quantification or cell sorting, as previously reported (Kiel et al., 
2005; Tothova et al., 2007; Fleming et al., 2008; Schindler et al., 2009; Xu   
et al., 2010). Fluorescence minus one (FMO) was used for setting the gating 
on control samples. For intracellular signaling analysis, Lineage cells were 
purified from BM and starved for 1 h in IMDM medium. Cells were then 
stimulated with SCF (50 ng/ml) for 5 min, fixed, permeabilized, and stained 
with antibodies against Sca-1, c-Kit, and phospho-ERK or phospho-AKT 
(Cell Signaling Technology) as previously reported (Kalaitzidis and Neel, 
2008; Chan et al., 2009). Percentages of the cells stained positive for phospho-
ERK or phospho-AKT in the gated LSK population were quantified by 
multiparameter FACS analyses.
Apoptosis and cell cycle analysis. Fresh BM cells were stained with biotin- 
labeled antibodies against lineage markers (Gr-1, Mac-1, B220, Ter119, 
CD4, CD8, and CD3e), followed by staining with streptavidin-conjugated 
APC-Cy7, anti–c-Kit-APC, and anti–Sca-1-FITC. The cells were then 
stained  with  anti–Annexin  V-PE  and  7-amino-actinomycin  D  using   
Annexin V-PE apoptosis Detection kit I (BD). Apoptotic (Annexin V+) cells in 
the gated LSK cell population were quantified by FACS. For LSK cell cycle 
analysis, fresh BM cells were stained with Pyronin Y (1 µg/ml) and Hoechst 
33342 (10 µg/ml). The cells were washed and then stained with the previ-
ously described antibodies. Subsequent LSK population gating and quantifi-
cation of the cells at G0, G1, and S/G2/M phases by FACS were performed 
as previously reported (Cheng et al., 2000; Xu et al., 2010).
Competitive repopulation assay. In brief, 106 BM cells (test cells) freshly 
harvested from Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/Mx1-Cre+ littermates 
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